Seeking Alpha

Alirocumab successful in nine Phase 3 trials

  • Regeneron Pharmaceuticals (NASDAQ:REGN) and partner Sanofi (NYSE:SNY) (OTCQB:SNYNF) report that their PCSK9 inhibitor alirocumab met its primary endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo or active comparator in nine Phase 3 clinical trials involving over 5,000 patients (including the MONO trial). The results were consistent with earlier alirocumab trials.
  • Three additional Phase 3 trials are ongoing.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector